Literature DB >> 3102088

Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.

E Wiltshaw, G Westbury, C Harmer, A McKinna, C Fisher.   

Abstract

Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients. All these patients treated at The Royal Marsden Hospital plus 30 more (total 67) have now been analysed. Single doses of 5 or 8 g/m2 ifosfamide were given over 24 h by infusion in dextrose saline together with 400 mg/m2 or 600 mg/m2, respectively, of mesnum every 4 h to give a total of 9 doses. A diuresis of 200 ml/hour was maintained during therapy. Treatment was repeated 3-weekly. CR was seen in 6 and PR in 10 patients. More recently doxorubicin was added to ifosfamide therapy in an attempt to improve on these results. At first only 20 mg/m2 doxorubicin was given but this was escalated to 40 mg/m2 and 60 mg/m2. Mesna has been given in higher dosage (5 g/m2 over 24 h), but otherwise the schedule is as above. In all 60 patients have been treated and most are now evaluable for response. Encephalopathy has been seen with both regimens. The incidence and patient characteristics are reported.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3102088     DOI: 10.1007/bf00647439

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  Encephalopathy associated with ifosphamide/mesna therapy.

Authors:  C A Meanwell; A E Blake; T N Latief; G Blackledge; J J Mould; D R Blake; I C Shaw; L Honigsberger; D Spooner; A C Williams
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

2.  [Chemotherapy in advanced sarcomas (author's transl)].

Authors:  W Bierbaum; K Bremer; N Firusian; M Higi; N Niederle; M E Scheulen; C G Schmidt; S Seeber
Journal:  Dtsch Med Wochenschr       Date:  1981-09-11       Impact factor: 0.628

3.  High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.

Authors:  R C Stuart-Harris; P G Harper; C A Parsons; S B Kaye; C A Mooney; N F Gowing; E Wiltshaw
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.

Authors:  K H Antman; D Montella; C Rosenbaum; M Schwen
Journal:  Cancer Treat Rep       Date:  1985-05
  4 in total
  6 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.

Authors:  S Toma; T Coialbu; L Biassoni; U Folco; C Gatti; G Canavese; A Giacchero; R Rosso
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.

Authors:  G Falkson; M R Chasen; H C Falkson
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

5.  Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.

Authors:  R E Hawkins; E Wiltshaw; J L Mansi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.

Authors:  B M Cantwell; J Carmichael; S Ghani; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.